Our findings reveal that USP22 plays a critical oncogenic role and represents a potential therapeutic target in NSCLC, and targeting USP22 will bring broad antitumor effects through suppression on multiple signaling pathways associated with cancer progression, which warrants further study. This evidence concerns the gene USP22 and non-small cell lung carcinoma.